About AmgenAmgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Pioneering Medicines
Amgen’s medicines treat serious illnesses. We have a presence in more than 50 countries worldwide and have reached millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. Our medicines typically address diseases for which the number of effective treatment options is limited, or they are medicines that provide a viable option to what is otherwise available.
Innovative Research
Understanding the fundamental biological mechanisms of human life is a defining feature of Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s deep and broad pipeline of potential new medicines. Amgen’s ‘biology first’ approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease, Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.
World-Class Manufacturing
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.
Contact Information
http://www.amgen.pt/about/amgen_portugal.html
Amgen Biofarmacêutica, Lda.
Edifício Dª.Maria I (Q60), Piso 2 – A,
Quinta da Fonte
2770-229 Paço d’Arcos
Tel: +351 214 220 550
Fax: +351 214 220 555
Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three…
Fresenius Kabi is a unique multinational pharma company in Portugal in that it is one of the very few that has production facilities and also exports. The Portuguese affiliate’s general…
In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat considering laws for generics had only been implemented a few…
“Portugal has incredible researchers and R&D for life sciences. Society in Portugal is starting to realize that there needs to be more emphasis on the market and more attention paid…
When PharmaBoardroom came to Portugal in 2007, price cuts, payment delays and changes to the health system with each successive government were but the first indications for the pharmaceutical…
Bene Farmacêutica was established in 2009 to expand the supply and presence of Bene-Arzneimittel in Portugal, having already sold products in the country for several decades. The affiliate’s managing director,…
“The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the…
Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at…
“Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we…
“We were, of course, impacted by the price cuts and we were pushed harder towards regaining the market quota and finding more business,” Miguel Lopes da Cunha says of Fapomed…
Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus…
Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus…
Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus…
See our Cookie Privacy Policy Here
